tirzepatide obesity nejm SURMOUNT-1 (NEJM 2022) tested — a dual GIP/GLP-1 receptor agonist — in 2,539 adults with and achieved up to 20.9% mean weight loss at the highest dose. 57% of participants New in the March 6,
Pay in 4 interest-free payments of $5.99 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
























